THLD MNTA AINV VHC RSO TORM DMND GMCR APKT AMSC
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Iron ore plunge hits Brazil
The 8.3% dive in the price of iron ore to $104.70 per ton is the 2nd largest one-day decline on record, and came following weekend data showing an 18.1% Y/Y slump in Chinese exports in February (a gain of 7.5% was expected). While miners like BHP and RIO remain optimistic about supply/demand dynamics (though dour on price prospects), Goldman - picking one analyst team - sees the market moving into surplus in H2 and prices falling below $100 per ton.
The Shanghai Composite fell 2.9% overnight and Brazil's Bovespa is down 2% in the early-going. Australia (EWA) declined 0.9% and the aussie (FXA) is off 0.6% to $0.9017.
The steelmaking ingredient is off 22% YTD and at its lowest price since October 2012.
In the meantime, the rumors are flying, including speculation a mill in China's Shanxi province defaulted on Friday and shut five to six furnaces. There's also chatter about banks looking to call in 20% of loans to private steel companies.
EWZ -2.1%, VALE -2.8%.
Brazil ETFs: EWZ, BRF, BRXX, EWZS, BRAQ, BRAZ, BZQ, BRZU, BRAF, UBR, BRZS, DBBR, FBZ
Base metal mining ETFs: XME, JUNR, PICK
SodaStream on the move
SodaStream (SODA +3.3%) shoots higher after fresh NPD data shows solid sales trends for the company last week.
Shares have crossed back over $42.
Seattle Genetics started at Buy
H.C. Wainwright initiates coverage of Seattle Genetics (SGEN) with a Buy rating and $65 price target citing the potential of its targeted antibody drug conjugate, Adcetris, to move into new cancer indications.
Shares currently trade at $51.
368 mutual funds have positions, down from 402 a year earlier.
juicy premium, trying to pick some puts myself..TSLA needs some reality gravity and that will drag down these little crack runners
Alexion ups guidance
Alexion Pharmaceuticals (ALXN) ups its 2014 EPS guidance to $4.37 to $4.47 from $3.70 - $3.80 citing improved reimbursement for Soliris in France.
Revenue guidance now $2.15B - $2.17B up from $2B - $2.02B.
Shares are up almost 3% premarket
GlaxoSmithKline raises exposure to India with $1.05B deal
GlaxoSmithKline (GSK +0.8% in London) increases its stake in Indian unit GlaxoSmithKline Pharmaceuticals Ltd to 75% from 50.7% for 64B rupees ($1.05B).
The subsidiary's shares will continue to trade publicly.
GSK offered to pay 3,100 rupees/share as part of an open offer to investors between February 18 and March 5. The company flagged its intention to raise its holding in the subsidiary in December.
GSK said the transaction "further increases our exposure to a strategically important market." The unit provides respiratory, cardiovascular and cancer drugs, antibiotics, and vaccines.
Just over a year ago, GSK paid $901M to raise its holdings in another Indian unit, GlaxoSmithKline Consumer Healthcare, to 72.5% from 43.2%
http://www.gsk.com/media/press-releases/2014/gsk-increases-stake-in-indian-pharmaceuticals-subsidiary-to-75-p.html
Regado's REG1 gets Fast Track designation
FDA designates Regado Biosciences' (RGDO) REG1 for anticoagulant therapy for use in patients with coronary artery disease during percutaneous coronary interventions (PCI) a Fast Track development program.
The product is currently in a Phase 3 clinical trial.
Five analysts rate the company at least a Buy.
http://seekingalpha.com/pr/9207183-fda-designates-regados-reg1-in-pci-as-a-fast-track-development-program
Quest completes acquisition
Quest Diagnostics (DGX) finalizes its previously-announced acquisition of Solstas Lab Partners Group.
On the basis of the purchase, the company ups its 2014 guidance to revenue growth of 2% - 4% versus the previous forecast of flat to down 2%.
EPS forecast now $3.95 - $4.15 up from $3.90 - $4.10.
Q1 EPS will be negatively impacted $0.10 due to harsh winter weather. Current consensus estimate is $0.93/share on revenues of $1.8B.
Northwest Bio gains key regulatory approval in Germany
Northwest Biotherapeutics (NWBO) gets a "Hospital Exemption" early access program for DCVax-L from German regulators. This means that the company may provide the product to patients for the treatment of Glioblastoma multforme and lower grades of gliomas outside of its clinical trial and charge full price.
The approval term is five years.
The German reimbursement authority approves DCVax-L eligibility for reimbursement from the Sickness Funds (health insurers). The specific level of payment will be negotiated by the company, hospitals and insurers.
http://seekingalpha.com/pr/9208223-nw-bio-announces-two-german-approvals-hospital-exemption-for-early-access-program-with-dcvax-l-and-eligibility-of-dcvax-l-for-reimbursement
Edwards Lifesciences upgraded
Wells Fargo upgrades Edwards Lifesciences (EW) to Outperform with a price target of $82 - $83, up from $67 - $69.
Catalysts for the upgrade include new transcatheter mitral valve implants that will boost 2016 revenue, an improved outlook for Sapien XT and upside potential from litigation with Medtronic (MDT) due to its infringement of two EW US patents.
EW closed Friday at $72.07.
Indian generic-drug firms involved in recalls
Indian generic-drug makers Sun Pharmaceutical Industries and Ranbaxy Laboratories have recalled batches of treatments in the U.S. following complaints of bottling mix-ups.
Sun Pharma diabetes tablets were found with an epilepsy medication, while Ranbaxy pulled two batches of its version of Pfizer's Lipitor cholesterol drug.
The recalls come amid increasing scrutiny of generic drugs manufactured in India and of Ranbaxy (RBXLY) in particular - four of its plants are banned from exporting to the U.S. after failing to meet FDA strictures.
Ranbaxy is owned by Japan's Daiichi Sankyo (DSKYF).
http://www.businessweek.com/news/2014-03-10/sun-pharma-ranbaxy-recall-some-generic-drug-batches-in-u-dot-s
William Blair jumps on board with Eagle Pharma
Eagle Pharmaceuticals (EGRX) gets another bullish rating. William Blair designates it Outperform.
BioCryst initiated at Buy
H.C. Wainwright begins coverage of BioCryst Pharmaceuticals (BCRX) with a Buy rating and $21 price target.
Friday's close was $11.46.
Consensus revenue estimates for 2014 and 2015 are $11.9M and $71M, respectively.
49 mutual funds have positions, down from 89 a year earlier.
Concert Pharma gets bullish ratings
UBS initiates coverage of Concert Pharmaceuticals (CNCE) with a Buy rating and $25 price target.
Wells Fargo initiates coverage with an Outperform rating and $22 price target.
The company debuted on February 13.
Shares closed Friday at $14.88.
FDA delays AdComm meeting for EnteroMedics device
The FDA has postponed a meeting of an advisory committee to discuss whether or not to recommend approving EnteroMedics' (ETRM) Maestro System therapy for treating morbid obesity.
The meeting will take place on June 17 rather than on May 29.
EnteroMedics said the delay is due to a scheduling conflict.
Notwithstanding what seems to be a rather innocuous reason for the postponement
http://seekingalpha.com/pr/9206283-enteromedics-announces-the-fda-has-rescheduled-the-advisory-committee-meeting-date-to-june-17-2014-for-review-of-maestro-r-rechargeable-system
IDIX was up 15% + pre market then faded..any news?
Smith & Nephew to market new technology to assist ortho surgeons
OrthoSensor announces that Smith & Nephew (SNN) will market its Verasense Sensor Assisted Surgery Technology to assist orthopedic surgeons when implanting SNN's Journey and Legion brands of Total Knee Systems.
The system enables evidence-based surgical decisions and delivers improved patient outcomes.
SNN shares are up 9% year to date.
On the hunt with the "pharmaceutical scouts"
The WSJ profiles "pharmaceutical scouts," who, like talent-spotters in baseball "trying to pick tomorrow's big-leaguers from farm teams," search outside their companies to find drug candidates that have the potential to become blockbusters.
In 2011, for instance, Johnson & Johnson's (JNJ) Peter Lebowitz helped his company beat competitors such as Novartis (NVS) to buy the rights to a blood-cancer drug from Pharmacyclics (PCYC) called Imbruvica.
The treatment was eventually approved in November for a rare lymphoma and for chronic lymphocytic leukemia in February. J.P. Morgan forecasts Imbruvica will generate $1.3B in revenue for J&J in 2017.
Half of J&J's drug pipeline is from outside the company, up from 20% in 2002.
Other related tickers: MRK, RHHBY, BMY, SNY, CELG, GSK
http://online.wsj.com/news/article_email/SB10001424052702304703804579384871050414310-lMyQjAxMTA0MDAwOTEwNDkyWj
WTW giddy up
PLUG is beyond epic..coulda been a life changer for anyone crazy enough not to have sold till now..wow
cures everything apparently. Like Windex from my Greek wedding movie,lol
3D printing stocks fall on Barron's piece
A weekend column titled "Beware 3-D Printing!" questions industry valuations, and suggests 3D Systems (DDD -4.2% premarket) could drop 80%.
The column highlights Whitney Tilson's critique of 3D Systems and the company's recent warning, argues 3D printing/additive manufacturing "remains slow and cumbersome," and notes the presence of rivals such as printing services firm Shapeways and leading metal printer maker EOS.
Barron's suggests software vendors Autodesk (ADSK) and Dassault (DASTY) are a better way to play the trend (ed: 3D printing use cases account for only a fraction of each company's sales), and notes the former's efforts to automate design work by leveraging real-life info. "The goal is for a designer to input a function, letting the computer dictate the most efficient design."
SSYS -3.1%. XONE -3.3%. VJET -1.7%.
It's a stock-pickers market!
To those who remember the risk on/risk off days of 2011 when the entire universe of assets seemingly moved together based on the utterings of some politician here or across the pond, today is quite a different matter. The instances of days in which more than 90% of S&P 500 stocks move together have all but vanished late last year and this year.
The 65-day average correlation of stocks fell to 0.52% in January vs. an average of 0.63% between 2009 and 2013 (it rose as high as 0.84% late in 2011).
Investors have responded by moving money into so-called actively managed strategies, with those funds seeing inflows of $1.3B this year on top of $9.8B in 2013. It's a small amount, but contrasts with $360B pulled out of such funds between 2009-2012.
Related ETFs: GURU, ALFA, CSM, QAI, ONN, OFF, BTAL, MCRO, CHEP, RALS, HDG, QEH, AGLS, CSLS, SIZ, QMN, CSMN
Firm to develop a pot spray for snoring
Northstar Global Business Services (MDIN) partners with Dixie Elixirs and Kush Creams on a THC oral spray for sleeping disorders such as snoring.
One of the most popular reasons doctors prescribe medical marijuana is, unsurprisingly, for patients experiencing difficulty sleeping.
No word on an offering that will deter trips to the refrigerator.
GM Z +SSS
Plug Power, FuelCell, alternative energy shares continue to soar
Last week's momentum in alternative energy shares continues into the new week, as Plug Power (PLUG +10.4%), FuelCell Energy (FCEL +11.6%), Ballard Power (BLDP +10.2%) and ZBB Energy (ZBB +15.1%) open sharply higher.
FCEL earnings
AstraZeneca ramping up virtual R&D model
AstraZeneca's (AZN) virtual iMed Oncology division signs an R&D deal with Korea Health Industry to identify early stage projects suitable for funding. The twelve most promising proposals will be chosen for development.The company formed iMed in 2012 as it eliminated 2,200 R&D jobs in an effort to cut costs and increase efficiency. Replacing the large centrally-located bureaucratic structure is a small in-house staff that interacts remotely with collaborators and contractors around the world.iMed's initial success in neuroscience prompted the move into oncology.
http://www.fiercebiotech.com/story/astrazeneca-leans-toward-virtual-rd-korean-oncology-deal/2014-03-07?utm_source=rss&utm_medium=rss
END unPOSing
He has the borrows? Lucky
Time to unPLUG? Anybody got borrows?.http://m.seekingalpha.com/article/2075013-pulling-the-plug-on-the-fuel-cell-mania?source=feed
Of course..but silver lining is after taxes u would only keep 250k..+/- a happy meal or three
This will be the next " Mary Jane" hot sector.
Medtronic on board to test orgasm device
North Carolina surgeon Stuart Meloy may have discovered a game changer for some women: a device that produces "orgasms on demand". He decided to pursue developing the product after witnessing a female patient's intense stimulation after he placed electrodes in her lower back for an undisclosed condition.The device consists of two electrodes that will be surgically inserted into certain nerves in the spinal column and a cigarette pack-size signal generator implanted in the upper buttock. The user presses a remote control button for stimulation.The device will be studied for women who have serious cases of orgasmic dysfunction where some women's brains interpret arousal as a fear response.Medtronic (MDT) has signed on to conduct tests.No decision on developing a mass market version has been disclosed.
Cant wait to see the PRs from the OTC tickers that hop on..
Been there many times..I try not to think of quantities I had of HLF at 25..TPX at 21..CREE 21s..DECK..GMCR obscene quantity mid 30s..
And JCP..YRCW very recently..
So many multi baggers unharvested..lol..but we need to enjoy what we have..there will always be another ticker to play and maybe one day we can actually hold on
Breathe deep..this too shall pass..
OT..Medtronic on board to test orgasm device
North Carolina surgeon Stuart Meloy may have discovered a game changer for some women: a device that produces "orgasms on demand". He decided to pursue developing the product after witnessing a female patient's intense stimulation after he placed electrodes in her lower back for an undisclosed condition.The device consists of two electrodes that will be surgically inserted into certain nerves in the spinal column and a cigarette pack-size signal generator implanted in the upper buttock. The user presses a remote control button for stimulation.The device will be studied for women who have serious cases of orgasmic dysfunction where some women's brains interpret arousal as a fear response.Medtronic (MDT) has signed on to conduct tests.No decision on developing a mass market version has been disclosed.
Is ticker(tickler?) A buy..buy..buy..buyyyyyyy?
Medtronic on board to test orgasm device
North Carolina surgeon Stuart Meloy may have discovered a game changer for some women: a device that produces "orgasms on demand". He decided to pursue developing the product after witnessing a female patient's intense stimulation after he placed electrodes in her lower back for an undisclosed condition.The device consists of two electrodes that will be surgically inserted into certain nerves in the spinal column and a cigarette pack-size signal generator implanted in the upper buttock. The user presses a remote control button for stimulation.The device will be studied for women who have serious cases of orgasmic dysfunction where some women's brains interpret arousal as a fear response.Medtronic (MDT) has signed on to conduct tests.No decision on developing a mass market version has been disclosed.
FRM nice classic V boinggggg